Neurotech International Limited (ASX: NTI) has initiated Monash Children’s Hospital as the first clinical site for its Phase 3 Beyond Harmony trial. The site is now open for patient screening and recruitment, marking the operational start of the pivotal trial evaluating NTI164 in paediatric patients with Autism Spectrum Disorder (ASD).
Monash Children’s Hospital is one of Australia’s leading paediatric medical and research facilities. Site initiation followed receipt of all required regulatory approvals, including HREC approval announced on 2 February 2026. This milestone represents an important step toward potential regulatory registration and potential commercialisation of NTI164.
Neurotech initiates Monash Children’s Hospital for pivotal Phase 3 autism trial
The Phase 3 Beyond Harmony trial is a multi-centre, randomised, double-blind, placebo-controlled study designed to evaluate the efficacy, safety and tolerability of NTI164 in children diagnosed with ASD. The study will assess key behavioural and functional endpoints aligned with regulatory guidance, with a focus on addressing core symptoms of ASD and associated neuroinflammatory pathways.
150 patients are planned for enrolment under an adaptive trial design. The design permits pre-specified modifications based on interim analyses while maintaining scientific and regulatory integrity. The trial is appropriately statistically powered and conducted in accordance with applicable regulatory guidelines and requirements.
The company is working closely with international clinical and regulatory experts to support study expansion, global alignment and execution of its broader development strategy. Additional clinical sites are expected to be initiated in the coming months as the study progresses.
When big ASX news breaks, our subscribers know first
What is a Phase 3 clinical trial and why does it matter?
Phase 3 trials represent the pivotal stage of drug development that determines whether a therapy can be approved by regulatory authorities. These large-scale studies validate earlier findings in a well-controlled setting, providing the evidence base required for registration submissions to bodies such as the Therapeutic Goods Administration (TGA) or Food and Drug Administration (FDA).
For NTI164, this trial is designed to rigorously evaluate the therapy in a well-controlled setting. Successful Phase 3 results form the foundation for regulatory submissions and unlock the pathway to commercialisation.
The three core purposes of Phase 3 trials are:
- Validation of efficacy in a larger, diverse patient population
- Safety confirmation through extended monitoring and broader demographic representation
- Regulatory pathway establishment by generating data that meets approval requirements
Phase 3 success represents the highest-value clinical milestone for biotech investors, as it de-risks the commercial pathway and positions the therapy for potential market entry.
Beyond Harmony trial design targets core autism symptoms
The Phase 3 Beyond Harmony trial employs a rigorous, multi-centre, randomised, double-blind, placebo-controlled design. The study targets paediatric patients diagnosed with Autism Spectrum Disorder, with a focus on addressing core ASD symptoms and associated neuroinflammatory pathways.
The adaptive design feature allows for pre-specified modifications based on interim analyses without compromising scientific integrity. This approach can potentially accelerate timelines while managing risk, maintaining regulatory rigour throughout the study.
| Parameter | Detail |
|---|---|
| Trial Name | Beyond Harmony |
| Phase | Phase 3 |
| Design | Multi-centre, randomised, double-blind, placebo-controlled |
| Patient Population | Paediatric ASD patients |
| Planned Enrolment | 150 patients |
The trial will assess key behavioural and functional endpoints aligned with regulatory guidance. These measures are designed to evaluate meaningful improvements in core ASD symptoms while monitoring safety and tolerability across the patient population.
NTI164’s mechanism of action in neuroinflammation
NTI164 is a proprietary, multi-constituent, GMP-grade standardised formulation containing CBDA-rich extracts and select minor cannabinoids. Preclinical and earlier clinical findings have demonstrated its potential to modulate neuroinflammatory signalling, immune dysregulation and upstream biological mechanisms implicated in neurodevelopmental disorders.
Prior clinical milestones supporting NTI164’s development include:
- Completed Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety
- Completed Phase I/II trials in ASD showing statistically significant and clinically meaningful results
- Completed Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS)
- Completed Phase I/II trial in Rett Syndrome
The strong Phase II/III data provides a foundation for the pivotal Phase 3 program, positioning NTI164 to enter the final development stage with demonstrated clinical efficacy and an established safety profile.
The next major ASX story will hit our subscribers first
CEO outlines significance of Phase 3 milestone
Anthony Filippis, CEO and Managing Director, emphasised the importance of the site initiation for both the company and families affected by ASD. His comments highlighted the rigorous evaluation ahead and the company’s commitment to advancing recruitment across multiple centres.
Anthony Filippis, CEO and Managing Director
“The initiation of our first Phase 3 site is a major milestone for the Company and for families affected by ASD. Beyond Harmony is designed to rigorously evaluate NTI164 in a well-controlled setting, and we look forward to progressing recruitment across multiple centres.”
Management’s confirmation of multi-site expansion signals execution capability and commitment to timely recruitment, both critical factors for maintaining development momentum.
What comes next for Neurotech
The company has outlined clear near-term catalysts for the Phase 3 Beyond Harmony program:
- Additional site initiations expected in the coming months
- Global alignment through collaboration with international clinical and regulatory experts
- Study expansion across multiple centres to support recruitment targets
The Phase 3 program positions NTI164 on a pathway to potential regulatory registration and potential commercialisation. Site initiations and recruitment updates are expected to provide ongoing newsflow for investors as the study progresses.
Don’t Miss the Next Biotech Breakthrough
Join 20,000+ investors receiving FREE breaking ASX biotech news delivered within minutes of release, complete with in-depth analysis. Get ahead on trial milestones, regulatory updates and market-moving announcements. Click the “Free Alerts” button at Big News Blast to receive real-time alerts the moment news breaks.